Tycho Heimbach | Fellow and Labhead
Novartis Pharmaceuticals Corporation

Dr. Tycho Heimbach is an Associate Director at Novartis Institutes for BioMedical Research in East Hanover, NJ. In his current role, he chairs a global team which reviews and makes recommendations for formulation and PK/PD strategies for all disease areas within the global DMPK function. He also serves as a representative on a global food-effect and IVIVC working groups where the main objective is to strengthen the biopharmaceutical sciences between different line functions at Novartis. His key responsibilities include bioavailability, formulation and ADME studies needed for regulatory submission in all major disease areas toward FIH studies. Tycho’s industrial work experience (20 years) encompasses various roles at Pfizer in formulation development, biopharmaceutics and DMPK departments and at BASF in polymer-chemistry R&D. Dr. Heimbach has been involved in the American Association of Pharmaceutical Scientist (AAPS) for more than 7 years serving as a chair/co-chair of the prodrug focus group. He has served treasurer/secretary and is currently the Vice Chair of the Physical Pharmacy and Biopharmaceutics (PPB) section. Dr. Heimbach received his B.S. in Chem. Engineering from the FH Druck College in Stuttgart, Germany and his M.S. in polymer science from the University of Detroit-Mercy, followed by his second M.S. (1997) and Ph.D. in Pharmaceutics (2003) from the University of Michigan. Dr. Heimbach has been an invited speaker to more than 15 national and international conferences and workshops speaking on topics of prodrugs, oral absorption, formulation-dependent human PK/PD projection and IVIVC.